Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Duodenal Neoplasms 1Colorectal Neoplasms 1Barrett Esophagus 1Attenuated familial adenomatous polyposis 1Adenomatous Polyposis Coli 1Adenocarcinoma Of Esophagus 1

Interventions

Specimen Handling 80Fluorouracil 74Oxaliplatin 69Magnetic Resonance Spectroscopy 61Leucovorin 58Gemcitabine 55Bevacizumab 55Biopsy 41Capecitabine 40Irinotecan 37Cisplatin 36Nivolumab 35pembrolizumab 33Cetuximab 33durvalumab 30Paclitaxel 27130-nm albumin-bound paclitaxel 27atezolizumab 20Folfox protocol 20Radiotherapy 17Carboplatin 17dehydroftorafur 15Taxes 15Cyclophosphamide 15fludarabine 13X-Rays 13Radiation 13trastuzumab deruxtecan 12Surgical Procedures, Operative 12Albumin-Bound Paclitaxel 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
obeticholic acid × Gastrointestinal × 30 days × Clear all
NCT05223036 2026-05-14

Testing Obeticholic Acid for Familial Adenomatous Polyposis

National Cancer Institute (NCI)

Phase 2 Terminated
15 enrolled
Gastrointestinal

Attenuated familial adenomatous polyposis, Duodenal Neoplasms, Adenomatous Polyposis Coli, Colorectal Neoplasms

NCT04939051 2026-05-13

Obeticholic Acid for Prevention in Barrett's Esophagus

National Cancer Institute (NCI)

Phase 2 Recruiting
30 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Barrett Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡